European Commission logo
español español
CORDIS - Resultados de investigaciones de la UE
CORDIS

Novel vaccine generation for the treatment of cancer. A glyco-nanomedial approach instructing T cells

Objetivo

There is an urgent need to develop vaccines for the induction of CD8+ T-cell immunity to treat cancer and infectious diseases. Dendritic Cells (DC) have shown potential to induce antigen specific CD8+ T-cell responses with the help of CD4+ T cells, yet the efficacy by which the induction is achieved still has its limitations. The main challenge is: (a) to increase targeting efficacy to the complete repertoire of DC subsets; (b) to trigger T-cell responses by the DC that is powerful enough to eliminate a tumour (c) to implement novel human read-out systems, that mimic he human body response to evaluate vaccine efficacy.

The aim of this research project is to develop new glycan-based nanomedicines targeted to DC to induce powerful T-cell responses. Within the scope of this research project these new glycan-based nanomedicines will be tested to (i) trigger a strong T-cell response to pathogens, (ii) induce a powerful and adequate T-cell response to self antigen in a tumour induced immune suppressive environment and (iii) render fundamental insights to establish a vaccine platform relevant for the treatment of cancer and infectious diseases.

GlycoTreat employs an unconventional, novel glycan biotechnology approach to target a multitude of DC subsets in the human skin to validate the groundbreaking hypothesis that the local administration and molecular size and glycan valency of the targeting compound affect the efficiency of the T-cell stimulating vaccine. This research project joins the chemical design of glyco-nanomedical vaccines with immunological outcomes in our advanced in-vitro, in-situ human skin and in-vivo mouse DC model systems. While crossing the established disciplinary boundaries between chemistry, biology and medicine, Prof. van Kooyk will generate a new field of expertise in vaccine development applied in the field of cancer treatment.

Convocatoria de propuestas

ERC-2013-ADG
Consulte otros proyectos de esta convocatoria

Régimen de financiación

ERC-AG - ERC Advanced Grant

Institución de acogida

STICHTING AMSTERDAM UMC
Aportación de la UE
€ 2 498 736,00
Dirección
DE BOELELAAN 1117
1081 HV Amsterdam
Países Bajos

Ver en el mapa

Región
West-Nederland Noord-Holland Groot-Amsterdam
Tipo de actividad
Research Organisations
Contacto administrativo
Yvette Van Kooyk (Mrs.)
Investigador principal
Yvette Van Kooyk (Prof.)
Enlaces
Coste total
Sin datos

Beneficiarios (2)